Iclaprim reduces the incidence and severity of Staphylococcus aureus-induced septic arthritis in a murine model

Huang, D. B., Noviello, S. and Gemmell, C.G. (2019) Iclaprim reduces the incidence and severity of Staphylococcus aureus-induced septic arthritis in a murine model. Access Microbiology, 1(7), e000052. (doi: 10.1099/acmi.0.000052) (PMID:32974543) (PMCID:PMC7481738)

Abstract

Staphylococcus aureus is the most common non-gonococcal aetiology of septic arthritis. The efficacy of iclaprim against S. aureus LS-1, a clinical strain identified from a patient with septic arthritis, was studied in MF1 mice to evaluate the activity of iclaprim, which is in clinical development, in preventing joint infections. Iclaprim (2.5–80 mg kg− 1) administered as a single dose via the tail vein reduced the incidence of S. aureus septic arthritis and mortality in an experimental murine model of septic arthritis.

• Item Type: Articles
• Additional Information: Funding information: This study was sponsored by Motif BioSciences, Inc.
• Status: Published
• Refereed: Yes
• Glasgow Author(s) Enlighten ID: Gemmell, Professor Curtis
• Authors: Huang, D. B., Noviello, S., and Gemmell, C.G.
• College/School: College of Medical Veterinary and Life Sciences > School of Infection & Immunity
• Journal Name: Access Microbiology
• Publisher: Microbiology Society
• ISSN: 2516-8290
• ISSN (Online): 2516-8290
• Published Online: 20 August 2019
• Copyright Holders: Copyright © 2019 The Authors
• First Published: First published in Access Microbiology 1(7): e000052
• Publisher Policy: Reproduced under a Creative Commons license